Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Lamet

Gastroenterology Hollywood, FL Medical Doctor

NPI 1972554731 CMS profile 44417

4350 Sheridan St Ste 101, Hollywood, FL 33021

Open in the dashboard

General payments

$7,051

322 records reported · program years 2019–2025

Research payments

$61,374

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$31,703 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Mark Lamet of Hollywood, FL is reported in the CMS Open Payments database as having received $7,051 across 322 general payments and $61,374 in research payments paid to them. Separately, studies naming them as principal investigator received $31,703 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,041 95
2024 General $1,369 46
2024 Research $14,608 4
2023 General $1,027 40
2022 General $770 23
2021 General $766 41
2021 Research $3,450 1
2020 General $255 14
2020 Research $7,411 4
2019 General $823 63
2019 Research $35,906 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Lamet
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Mark Lamet were reported at $2,041. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Mark Lamet Gastroenterology median Middle half National median
2019 $823 $417 $126–$1,100 $163
2020 $255 $224 $74–$624 $114
2021 $766 $352 $106–$1,054 $132
2022 $770 $448 $129–$1,270 $149
2023 $1,027 $533 $150–$1,390 $160
2024 $1,369 $605 $160–$1,606 $164
2025 $2,041 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,624 62 payments
  2. Janssen Biotech, Inc. $954 55 payments
  3. Madrigal Pharmaceuticals $751 22 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $718 43 payments
  5. Celgene Corporation $450 16 payments
  6. Janssen Scientific Affairs, LLC $365 3 payments
  7. Braintree Laboratories, Inc. $299 24 payments
  8. Gilead Sciences, Inc. $264 17 payments
  9. Intercept Pharmaceuticals, Inc. $255 12 payments
  10. Ipsen Biopharmaceuticals, Inc $174 11 payments
  11. Other $1,197 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,620 302 payments
  2. Education $248 18 payments
  3. Consulting Fee $183 2 payments
Products named General payments · program years 2019–2025
  1. STELARA $961 51 payments
  2. RINVOQ $882 24 payments
  3. XIFAXAN $833 50 payments
  4. TREMFYA $718 25 payments
  5. REZDIFFRA $441 19 payments
  6. SIMPONI ARIA $433 35 payments
  7. SIMPONI $433 35 payments
  8. ZEPOSIA $352 15 payments
  9. SKYRIZI Immunology $342 12 payments
  10. SKYRIZI Immunology $295 13 payments
  11. Other $3,171 182 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Celgene Corporation $56,833 9 payments
  2. Eli Lilly and Company $2,641 3 payments
  3. AbbVie, Inc. $1,900 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,866

Median for Gastroenterology: 569

Drug cost

$179,574

Median for Gastroenterology: $104,976

Branded share of claims

43.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 85 $50,431
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 211 $35,799
Relistor Methylnaltrexone Bromide Brand 13 $27,035
Creon Lipase/Protease/Amylase Brand 19 $25,446
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 347 $24,526
Cholestyramine Cholestyramine (With Sugar) Brand 32 $2,360
Pantoprazole Sodium Generic 264 $2,055
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 12 $1,959
Lactulose Generic 83 $1,621
Dicyclomine Hcl Generic 124 $1,511

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$50,216

Medicare's payments for the services billed

Medicare patients

197

Average age 75

Services billed

460

99 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Chronic kidney disease 45%
Diabetes 44%
Ischemic heart disease 42%
Depression 38%
Heart failure 29%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $170
$170 — —
RESMETIROM
  • Madrigal Pharmaceuticals $160
$160 — —
REZDIFFRA
  • Madrigal Pharmaceuticals $150
$150 — —
TREMFYA
  • Janssen Scientific Affairs, LLC $118
  • Janssen Biotech, Inc. $31
$148 — —
SKYRIZI
  • AbbVie, Inc. $142
$142 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record